Related Experiment Videos

Interferon affects nuclear proteins in cells of clinically sensitive chronic myelogenous leukemia patients

O M Howard1, M Talpaz, H Kantarjian

  • 1Department of Hematology, University of Texas M.D. Anderson Cancer Center, Houston, TX.

Blood
|September 15, 1990
PubMed

Insights

Cytoplasmic proteins in chronic myelogenous leukemia (CML) alter gene activity. Interferon-alpha (IFN-alpha) treatment reduces this effect, suggesting a link between IFN-alpha

Area of Science:

  • Molecular Biology
  • Oncology
  • Virology

Background:

  • Chronic myelogenous leukemia (CML) is a myeloproliferative neoplasm characterized by the Philadelphia chromosome.
  • Interferon-alpha (IFN-alpha) is a cytokine used in CML treatment, but its precise mechanism of action remains incompletely understood.
  • Transcriptional enhancers regulate gene expression, and their interaction with nuclear proteins is crucial for cellular function.

Purpose of the Study:

  • To investigate the role of cytoplasmic factors in CML cells concerning the regulation of interferon-inducible genes.
  • To explore the interaction between CML cytoplasmic proteins, nuclear proteins, and DNA complexes involved in gene transcription.
  • To determine if IFN-alpha modulates the activity of these cytoplasmic factors and if this correlates with clinical response.

Main Methods:

  • Preparation of cytoplasmic protein extracts from CML cells.
  • Electrophoretic mobility shift assays (EMSA) to analyze protein-DNA complex formation and alterations.
  • Treatment of CML cells with IFN-alpha and assessment of its effect on cytoplasmic protein activity.

Main Results:

  • Cytoplasmic extracts from CML cells exhibited an activity that modified the electrophoretic mobility of nuclear protein-DNA complexes binding to interferon-inducible gene enhancers.
  • Exposure of CML cells to IFN-alpha significantly diminished the influence of these CML cytoplasmic proteins on the nuclear protein-DNA complexes.
  • Clinical responsiveness to IFN-alpha in CML patients correlated with the sensitivity of these nuclear protein-DNA complexes to IFN-alpha-induced mobility changes.

Conclusions:

  • The findings suggest that IFN-alpha's therapeutic effect in CML may involve a pathway impacting posttranslational modifications of nuclear proteins.
  • Cytoplasmic factors in CML cells play a role in regulating the transcriptional machinery of interferon-inducible genes.
  • The modulation of nuclear protein-DNA complex dynamics by IFN-alpha is a potential biomarker for treatment response in CML.

Related Concept Videos